• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

What is the Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation?

image_pdfFavoriteLoadingFavorite

PURPOSE:

Electromechanical morcellation has been instrumental in advancing the field of minimally invasive gynecologic surgery. Recently, the technique has come under scrutiny due to the concern of inadvertent morcellation and dissemination of malignant cells in the setting of uterine cancer (for example leiomyosarcoma). Currently, there is limited data as to whether there is a difference in safety between vaginal and peritoneal morcellation. This study by Wasson et al. (Journal of Minimally Invasive Gynecology, 2017) sought to determine the incidence of occult uterine malignancy at the time of vaginal hysterectomy and secondarily, peri-operative data as well as long-term patient outcomes.

METHODS:

Retrospective Cohort Study

RESULTS:

2,296 women across three institutions underwent total vaginal hysterectomy. 73.39% of women did not have vaginal morcellation and 611 women did undergo vaginal morcellation via cold-knife wedge resection. All patients requiring morcellation had benign indications for hysterectomy and all surgeries were performed by gynecologists with subspecialty training in minimally invasive surgery. In the non-morcellation group, occult malignancy was found in 5 patients (0.3%) of patients; Stage IA, grade I endometrial adenocarcinoma in 4 patients (0.24%), and low-grade stromal sarcoma was found in 1 patient (0.06%). In the morcellation group, 5 patients (0.82%) had an occult uterine malignancy; stage IA, grade I endometrial adenocarcinoma in 3 patients (0.49%) and low grade stromal sarcoma in 2 patients (0.33%). There were no cases of uterine sarcoma. In all 5 patients, the initial indication for hysterectomy was abnormal uterine bleeding and all patients underwent uterine sampling and pelvic imaging. All the patients have remained disease-free and no deaths have occurred with a mean disease-free survival of 48.33 months (range, 33-67 months) for those with endometrial adenocarcinoma and 42.0 months (range, 19-65 months) for patients with stromal carcinoma. The authors recognize limitations of the study, including retrospective design, limited sample size and subspecialty surgeons. The authors conclude that for patients undergoing uncontained vaginal hysterectomy with morcellation, prognosis in the setting of occult endometrial carcinoma or low-grade stromal sarcoma was not adversely affected.

Learn More – Primary Sources:

Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Endometrial Hyperplasia – Current Nomenclature and Treatment
Best Antibiotic Strategy to Prevent Infection After Hysterectomy
High-Intensity Focused Ultrasound – An Option for Fibroids

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site